Chennai Journal

Dry Eye Disease Market and Epidemiology Forecast 2032: Population Data, Treatment Market, Drugs, Companies and Competitive Intelligence by DelveInsight

 Breaking News
  • No posts were found

Dry Eye Disease Market and Epidemiology Forecast 2032: Population Data, Treatment Market, Drugs, Companies and Competitive Intelligence by DelveInsight

April 20
19:10 2023
Dry Eye Disease Market and Epidemiology Forecast 2032: Population Data, Treatment Market, Drugs, Companies and Competitive Intelligence by DelveInsight
Dry Eye Disease Market

(New York, USA) DelveInsight’s Dry Eye Disease Market Insights report includes a comprehensive understanding of current treatment practices, Dry Eye Disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

 

To know more about the Dry Eye Disease market trends and dynamics, click here: Dry Eye Disease market forecast

 

Key facts from the Dry Eye Disease Market Report:

  • As per DelveInsight analysis, the Dry Eye Disease market is anticipated to witness growth at a considerable CAGR.
  • According to DelveInsight’s analysis, females are more affected by Dry Eye Disease than males.
  • Leading Dry Eye Disease companies such as Novartis AG, AbbVie, Sun Pharmaceutical, Santen Pharmaceutical, AFT Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceutical, OASIS Medical, Bausch & Lomb, TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, and others are developing novel Dry Eye Disease drugs which can be available in the Dry Eye Disease market in the upcoming years.
  • The Dry Eye Disease drugs in different phases of pipeline include PL9643, NOV03, CyclASol, MC2-03, and others.
  • The total Dry Eye Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major Dry Eye Disease markets.

 

Dry Eye Disease Overview

Dry eye disease (DED), also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a common condition when eyes do not produce enough tears or the tears evaporate too quickly. As tears are essential to lubricate and nourish the eye, the condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for DE include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of the tear layer. 

It is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. It can affect one or both eyes, and it can lead to inflammation. 

The main symptom of dry eye is a dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases. Sometimes, it is also associated with a stringy discharge and blurred, changing vision. Besides, the symptoms are found to worsen in dry weather, with low humidity, and higher temperatures. Having dry eyes for a while can lead to tiny abrasions on the surface of the eyes. In advanced cases, the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells.

 

Download the report to understand which factors are driving Dry Eye Disease epidemiology trends – https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights

 

Dry Eye Disease Epidemiology Segmentation

  • Prevalent Population of Dry Eye Disease
  • Age-Specific Prevalent Cases of Dry Eye Disease
  • Gender-Specific Cases of Dry Eye Disease
  • Diagnosed and treatable Population of Dry Eye Disease

 

Dry Eye Disease Treatment Market 

The Dry Eye Disease management aims to relieve the discomfort and prevent damage to the cornea, at the front of the eye. Currently, the available treatment options for DED depend on the severity of the condition. They may include medication, surgery, and others (eyelid therapy [warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles]). 

Dry Eye Disease Treatment depends on the underlying cause. Artificial tears are the usual first-line treatment. Wrap-around glasses that fit close to the face may decrease tear evaporation. Stopping or changing certain medications may help. The medication cyclosporine or steroid eye drops may be used in some cases. Another option is lacrimal plugs that prevent tears from draining from the surface of the eye. Dry eye syndrome occasionally makes wearing contact lenses impossible.

 

To know more about Dry Eye Disease treatment, visit – https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights

 

Dry Eye Disease Pipeline Therapies and Companies

  • Palatin Technologies: PL9643
  • Novaliq: NOV03
  • Novaliq: CyclASol
  • Mc2 therapeutics: MC2-03
  • And many others.

 

Learn more about the latest Dry Eye Disease clinical trials and breakthroughs by requesting for a free sample report – https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights

 

Scope of the Dry Eye Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Dry Eye Disease Companies:  Novartis AG, AbbVie, Sun Pharmaceutical, Santen Pharmaceutical, AFT Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceutical, OASIS Medical, Bausch & Lomb, TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics and others
  • Key Dry Eye Disease drugs: PL9643, NOV03, CyclASol, MC2-03, and others
  • Therapeutic Assessment: Dry Eye Disease current marketed and emerging therapies
  • Dry Eye Disease Market Dynamics:  Dry Eye Disease market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement

 

Discover more about Dry Eye Disease drugs in development – https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights

 

Table of Contents

1. Dry Eye Disease Market Key Insights

2. Dry Eye Disease Market Report Introduction

3. Dry Eye Disease Market Overview at a Glance

4. Dry Eye Disease Market Executive Summary

5. Disease Background and Overview

6. Dry Eye Disease Treatment and Management

7. Dry Eye Disease Epidemiology and Patient Population

8. Dry Eye Disease Patient Journey

9. Dry Eye Disease Emerging Drugs

10. 7 Major Dry Eye Disease Market Analysis

11. Dry Eye Disease Market Outlook

12. Potential of Current and Emerging Dry Eye Disease Therapies

13. KOL Views

14. Dry Eye Disease Market Drivers

15. Dry Eye Disease Market Barriers

16. Dry Eye Disease Unmet Needs

17. SWOT Analysis

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting